Matrixx update
This article was originally published in The Tan Sheet
Executive Summary
Firm reports expected EPS loss in $0.08 to $0.12 range for second quarter (ended June 30), with net sales flat or up 10% compared to the year-ago period. Second quarter sales account for 10% of its "extremely seasonal" business and was impacted by an abrupt end to the cold season and resultant low levels of reorders, CEO Carl Johnson says July 1. The exec said sales of the firm's Zicam cold remedy "continue to grow at retail despite the reduction in cold-related consumer demand." Matrixx affirmed its full-year guidance of 30% increases in sales and earnings over 2003 net sales and earnings of $43.5 mil. and $3.3 mil., respectively...
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.